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Efficacy of IVIG for Treatment of De-Novo Donor Specific Antibodies in Renal Transplant Recipients
Lynsey A Biondi, MD, Michael J Moritz, MD and Matthew DeFulvio, Department of Surgery
Lehigh Valley Health Network, Allentown, Pennsylvania

Abstract
• Development of Donor Specific Antibodies (DSA) is linked to
worsened outcomes in renal transplant recipients. Intravenous
immunoglobulin (IVIG) is an immune-modulator utilized in
treatment of antibody mediated rejection. A retrospective
review of kidney transplant cases at Lehigh Valley Health
Network (LVHN) from January 2009 to June 2014 was
performed to evaluate the efficacy of IVIG in treatment of new
DSAs. All patients undergoing renal transplant at LVHN are
cross-match compatible at the time of procedure.
Desensitization is not utilized. All highly sensitized patients
(PRA>50%) receive prophylactic IVIG monthly x 4 months
post-transplant. Study patients that tested positive for DSA
post-transplant were treated with additional IVIG (0.5g/kg
monthly). 95 patients were treated with IVIG during the study
period. Of 55 patients with newly positive DSA, 24 of these
cleared the DSA after IVIG treatment. IVIG was more effective
in clearance of class I than class II DSA. Highest rates of graft
loss occurred in patients that tested positive for both a class I
and class II DSA. Conclusion: 1. IVIG can be a useful in
eliminating DSA post-renal transplant. 2. IVIG is effective in
eliminating Class I DSA. 3. Class II DSA can be difficult to
eliminate and requires further investigation.

Background

Results

Total Patients
Total percent
New DSA
DSA clearence
AMR

Prophylactic IVIG (Sensitized patients) Non Prophylactic patients (nonsensitized)
61/95
34/95
64.20%
35.80%
32.8% (20)
100%
45% (9/20)
44.1% (15/34)
35% (7/20)
64.7% (22/34)

• Of the 293 patients who received kidney
transplantation at Lehigh Valley Health
Network in the study period, 95 were
treated with IVIG. 55 patients that were
treated with IVIG had a positive DSA
(57.8%). 24 (43.6%) of those patients
cleared the DSA after treatment with IVIG.
Of the remaining 31 patients, 28 did not
clear the DSA and 3 patients expired during
the study interval.

• Intravenous immunoglobulin (IVIG) is a medication
that has emerged as a useful tool in modulating
immunity, treatment of antibody mediated rejection
(AMR), and in desensitization protocols Studies
have still not demonstrated optimal regimens for
treatment of new DSA. The purpose of this study
was to investigate the effectiveness of IVIG in
elimination of DSAs.

Methods
A retrospective chart review was performed of all kidney transplant
patients at Lehigh Valley Health Network who were treated with IVIG
post transplantation from January 2009 to June 2014. All patients
were cross match compatible (no DSA presence at time of transplant).
All highly sensitized patients (PRA greater than 50%), were
prophylactically treated with 0.5g/kg of IVIG monthly for four doses
beginning at the time of transplant.
Patients that tested positive for DSA post-transplant were biopsied
and treated monthly with 0.5g/kg of IVIG until clearance of DSA. Time
to DSA clearance, dates of graft loss, AMR, and development of Class I
versus Class II DSA were noted.

P=0.020

P=0.05

61 of the 95 (64.2%) patients received prophylactic IVIG.
Out of those, 41/61 (67.2%) never developed a DSA
while 20/61 (32.8%) did. Out of the 20 that developed a
DSA, 9 cleared the DSA. 34 non-sensitized patients (12%
total non-sensitized transplants) developed DSAs and
then received treatment with IVIG.
IVIG was more effective in the clearance of class I DSA’s
than class II. Following treatment with IVIG, 8/12
(66.7%) of the Class I DSAs cleared and 11/26 (42.3%) of
the class II DSAs cleared (p=0.05). Lowest rates of graft
loss occurred in patients with a class I DSA, followed by
class II, and lastly if a patient had both (p=0.02).

Conclusions
• 1. IVIG can be a useful in eliminating DSA post-renal
transplant.
• 2. IVIG is effective in eliminating Class I DSA.
• 3. Presence of Class II DSA is associated with higher
rates of graft loss. Class II DSA can be difficult to
eliminate and requires further investigation, possibly in
combination with biologic agents.
• 4. Limited numbers of patients at this time make
statistically significant results difficult to achieve. Further
investigation is necessary.
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